NA-921 by Biomed Industries for Fragile X Syndrome: Likelihood of Approval
NA-921 is under clinical development by Biomed Industries and currently in Phase III for Fragile X Syndrome.
NA-921 is under clinical development by Biomed Industries and currently in Phase III for Fragile X Syndrome.
What's Your Reaction?
